Regeneron Pharmaceuticals Inc (NASDAQ:REGN) CFO Robert E. Landry sold 400 shares of the company’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $612.57, for a total value of $245,028.00. Following the completion of the transaction, the chief financial officer now owns 24,334 shares of the company’s stock, valued at $14,906,278.38. The transaction was disclosed in a filing with the SEC, which is available at this link.
Shares of NASDAQ:REGN opened at $622.45 on Friday. Regeneron Pharmaceuticals Inc has a 52-week low of $271.37 and a 52-week high of $646.33. The firm has a market capitalization of $68.61 billion, a P/E ratio of 31.28, a P/E/G ratio of 1.97 and a beta of 0.58. The stock has a 50 day moving average price of $595.43 and a 200-day moving average price of $478.59. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.49 and a current ratio of 4.21.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $6.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.13 by $0.47. Regeneron Pharmaceuticals had a return on equity of 24.94% and a net margin of 28.56%. The firm had revenue of $1.83 billion during the quarter, compared to analyst estimates of $1.81 billion. During the same quarter in the prior year, the company earned $4.45 EPS. The business’s revenue was up 6.8% compared to the same quarter last year. On average, equities analysts forecast that Regeneron Pharmaceuticals Inc will post 23.48 EPS for the current fiscal year.
REGN has been the subject of a number of research reports. JPMorgan Chase & Co. upped their price objective on Regeneron Pharmaceuticals from $375.00 to $429.00 and gave the stock a “neutral” rating in a report on Wednesday, April 15th. Credit Suisse Group upped their price objective on Regeneron Pharmaceuticals from $605.00 to $700.00 and gave the stock an “outperform” rating in a report on Wednesday, June 24th. Jefferies Financial Group increased their target price on Regeneron Pharmaceuticals from $657.00 to $691.00 and gave the company a “buy” rating in a report on Friday, June 12th. Canaccord Genuity increased their target price on Regeneron Pharmaceuticals from $575.00 to $630.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Finally, BidaskClub cut Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, June 10th. Fifteen investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $550.64.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Recommended Story: Arbitrage
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.